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Abstract
Background: Crohn’s disease (CD) is a chronic immune-me-
diated disorder of the gastrointestinal tract. The pathophys-
iological understanding of this disease is limited and no cu-
rative therapy is available so far. Therefore, most patients 
require long-lasting or even life-long immunosuppressive 
therapies for the suppression of symptoms to improve qual-
ity of life and reduction of long-term risks. However, in a 
relevant subgroup of patients, these therapeutic goals can-
not be sufficiently attained. Summary: Clinically established 
therapies in active CD comprise corticosteroids and immu-
nosuppressants such as azathioprine. After the introduction 
of anti-TNFα (Tumor necrosis factor alpha) antibodies, other 
biologicals (e.g., vedolizumab and ustekinumab) have also 
been approved. New drugs in the pipeline like filgotinib, 
upadacitinib, risankizumab or rifaximin could improve the 
therapy of CD in the near future. Thus, an individualized 
therapy management, based on optimal selection of thera-
peutic agents will become more important. Additionally, 
the local application of mesenchymal stem cells might be 
helpful in the management of fistulas. Key Messages: The 
targeted biological therapeutic agents (anti-TNFα antibod-
ies, vedolizumab, ustekinumab) are well established for 
therapy in CD. There are several new substances in the pipe-
line with promising results in phase II trials (filgotinib, rifax-
imin, risankizumab, upadacitinib). The upcoming extension 
of the therapeutic arsenal will require methods for an opti-
mized selection of substances, thus enabling a more indi-
vidualized therapy. © 2018 S. Karger AG, Basel
Introduction
Inflammatory bowel diseases are marked by a chronic, 
immune-mediated inflammation of the gut [1]. In the 
case of Crohn’s disease (CD), the inflammation may be 
observed in all parts of the gastrointestinal tract. The ori-
gin of this disease remains unclear but seems to result 
from a combination of genetic predisposition and mul-
tiple environmental factors [2]. The intestinal microbi-
ome could be involved in the pathogenesis [3]. According 
to epidemiological data, the incidence of CD is increasing 
[4]. Patients are affected by abdominal pain, (bloody) di-
arrhea, fatigue and are at risk of fistulas, malnutrition, 
osteoporosis and colon cancer in the long term [5].
Importantly, no curative therapy for CD is available. 
In order to improve the quality of life and reduce risk of 
long-term complications, most patients require an im-
munosuppressive therapy for many years or even their 
whole life [1, 6]. These advantages must outweigh the po-
tential side effects of the therapeutic substance(s) [7].
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In the following sections, we discuss therapy objec-
tives, present established and new substances and address 
the topic of individualized therapy.
Therapy in CD – Goals and Controls
The therapeutic goals in CD are reduction of symp-
toms, improvement of life quality and prevention of long-
term complications. In the previous years, an increasing 
number of clinical studies demonstrated the relevance to 
reach mucosal healing as well [8]. Mucosal healing is as-
sociated with a reduction of the need of surgery [9] and 
longer time of remission [10]. However, there is lack of 
agreement about the definition of mucosal healing so far 
[11, 12]. Finally, the suppression of inflammatory activity 
could avoid long-term risks like colorectal carcinoma and 
postoperative short bowel syndromes. The therapeutic 
efficacy of the applied drugs should outweigh their side 
effects. Typical adverse effects of some immunosuppres-
sive substances such as azathioprine are an increased risk 
for infections and possibly a low risk for lymphoma and 
non-melanoma skin cancer in the long term [7, 13, 14]. 
Moreover, there are substance-specific side effects like 
azathioprine-induced acute pancreatitis [15] or inflix-
imab-associated anaphylactic reactions [16].
Clinical assessments with the determination of the CD 
activity index (CDAI; remission: <150) or the Harvey-
Bradshaw-Index (remission: <5) may be helpful for the es-
timation of inflammatory activity. This should be comple-
mented by the measurement of biomarkers like C-reactive 
protein (CRP) or calprotectin [17]. In the CALM-Study, 
the consequent adaption of immunosuppressive therapy 
based on these biomarkers and symptoms led to a higher 
rate of mucosal healing after 1 year when compared to the 
pure symptom-driven therapy management (45.9 vs. 
30.3%). The frequency of adverse effects for both groups 
was similar [18]. In patients after ileocecal resection, cal-
protectin correlates better with the endoscopic degree of 
inflammation than CRP, leukocytes or the CDAI [19]. 
Colonoscopy should be performed in non-responders, 
flares or before de-escalation of therapy. In the case of a 
non-response or severe flare, testing for a potential infec-
tion with Clostridium difficile or cytomegalovirus should 
be considered before escalation of therapy [17]. In patients 
with extensive small bowel or ileocaecal disease, regular du-
plex sonographic control is an additional option. Another, 
more sensitive method for the detection of inflammation 
in the small intestine is capsule endoscopy [20]. Possibly, 
multispectral optoacoustic tomography could improve the 
sensitivity for non-invasive detection of inflammation in 
the gut in the future [21, 22]. Direct drug-monitoring could 
also become important in the future [23]. 
Approved Substances – State of the Art
In the previous years, the number of available drugs for 
the therapy of CD has remarkably increased. Substance-
specific characteristics are described in the following sec-
tions and Figure 1 gives an overview about the therapeu-
tic management.
Glucocorticoids
Glucocorticoids have been used for the therapy of CD 
since decades and they have pleiotropic effects. The immu-
nosuppressive effects are achieved by binding to intranu-
clear receptors, which regulate the activation of various 
transcription factors (e.g., Activator Protein 1). This in 
turn leads to the inhibition of NFκB (nuclear factor kappa-
light-chain-enhancer of activated B cells) activation and 
thus finally decreases the production of pro-inflammatory 
cytokines (e.g., tumor necrosis factor alpha [TNFα]) [24]. 
Due to the fast therapeutic effect and potent immunosup-
pression, this class of substances is suitable for the therapy 
of flares in CD [25]. However, due to multiple side effects 
and especially the lack of potency to maintain remission 
[26], it is not reasonable to use glucocorticoids in the long 
term. Glucocorticoids can worsen diabetes mellitus and 
osteoporosis [27] and may induce steroid acne, alopecia 
and depression. Adrenal insufficiency can be avoided by 
the slow tapering of systemic glucocorticoids. Systemic 
side effects can be reduced by the usage of budesonide, 
which has a pronounced first-pass effect. According to the 
European Crohn’s and Colitis Organisation guidelines 
from 2016, budesonide is preferred in the case of mild in-
flammation and equivalent to systemic steroids in moder-
ately active, localized ileocaecal CD [8, 28]. However, in 
more severe cases or extended disease conditions, conven-
tional steroids are more effective in attaining remission [8]. 
Immunomodulators – Thiopurines and Methotrexate
Thiopurines are Rac1 blockers and purine antimetab-
olites, whereby azathioprine is a precursor of 6-mercap-
topurine. Due to its great effect latency, these drugs are 
not suitable to treat flares of CD [29] but can maintain 
remission in a fraction of CD patients [30, 31]. Typical 
side effects of thiopurines are, for example, fatigue, acute 
pancreatitis, increased susceptibility for infections and in 
the long-term potentially lymphoma and non-melanoma 
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skin cancer [8, 32]. The strongest risk factor for azathio-
prine-induced acute pancreatitis is smoking [15]. Be-
cause of convincing data for biologicals, immunomodu-
lators were less frequently used in recent years [32]. On 
the one hand, the SONIC study could demonstrate that 
the anti-TNFα antibody infliximab is superior to azathio-
prine therapy in maintenance of remission in CD. On the 
other hand, the combination of both substances was even 
more effective, which encourages the use of immuno-
modulators as combination partners [33]. Moreover, a 
phase II study was able to demonstrate that a delayed re-
lease formulation of 6-mercaptopurine is able to improve 
the ratio between efficacy and adverse side effects [34]. 
Methotrexate not only inhibits the dihydrofolate reduc-
tase but also inhibits cytokine and eicosanoid synthesis 
[35]. For the subcutaneous or intramuscular application, a 
probably positive effect concerning induction and mainte-
nance of remission in patients with CD has been demon-
strated [36, 37]. For these indications, methotrexate is an 
alternative after the usage of thiopurines and biologicals 
[8]. Controls of liver enzymes are necessary during therapy.
Anti-TNFα Agents
Several anti-TNFα antibodies have been approved for 
clinical use in CD (infliximab [38], adalimumab [39, 40] in 
the United States and Switzerland along with certolizumab 
[41]). These substances induce apoptosis of CD4+-T-cells 
and macrophages and influence the cytokine milieu by 
binding to soluble and membrane-bound TNF [42]. Due 
to the lack of an Fc region in certolizumab, some effects are 
only observed with adalimumab and infliximab [43].
Anti-TNFα antibodies are efficient in inducing and 
maintaining remission in patients with CD [38–41]. Ac-
cording to some metanalyses, there are no relevant differ-
ences in therapeutic efficacy between adalimumab and in-
fliximab, whereas certolizumab might be less effective [44–
46]. However, there are no head-to-head studies, which 
make a direct comparison difficult [8]. As with other sub-
stances, only a subgroup of patients profits clinically and 
endoscopically from a therapy with anti-TNFα antibodies. 
For approximately one third of the patients, a complete 
remission can be induced and only in half of these patients 
remission can be maintained for at least 12 months [47]. 
Rarely, anti-TNFα antibodies can induce an allergic re-
action. The main side effect is a probably increased risk for 
infections, especially a reactivation of latent tuberculosis 
[7, 13]. There is also a theoretically increased risk for ma-
lignant diseases; however, a final proof is still absent [48]. 
Anti-TNFα antibodies are well suited for the mainte-
nance of remission and are potent inductors of remission 
in steroid-refractory or steroid-intolerant patients. Other 
fields of possible applications are therapy of extensive 
CD, arthritis associated with CD, localized but severely 
active ileocaecal CD or fistulating disease [8]. 
A significant improvement in clinical and endoscopic 
outcome was observed by the adaption of the dose of adali-
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Fig. 1. Overview of therapeutic options in Crohn’s disease (based 
on ECCO [European Crohn’s and Colitis Organisation] Guide-
lines 2016, modified [8]). The acute therapy depends on the loca-
tion and the degree of inflammatory activity. The sacrifice of 
 nicotine should be recommended to each patient [60]. The re-
quirement for long-term immunosuppression depends on indi-
vidual risk factors (young age at diagnosis, demand for steroids 
during the first flare, the presence of an ileocolonic disease or peri-
anal disease and no sufficient mucosal healing). Surgical options 
should be considered during therapeutic management. * Alpha-
betic  sequence; Selection of the substance according to the indi-
vidual risk-benefit ratio, patient’s preferences and economic as-
pects. PPI, proton-pump inhibitor; TNFα, tumor necrosis factor 
alpha.
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mumab not only symptom-driven but also based on CRP 
and calprotectin (CALM-Study) [18]. In the case of insuf-
ficient response or loss of efficacy, it can be worth trying 
another anti-TNFα antibody. In a placebo-controlled mul-
ticenter study with patients being affected by adverse ef-
fects of infliximab or insufficiently controlled disease un-
der this substance, adalimumab was able to induce remis-
sion (adalimumab vs. placebo: 52 vs. 34%) [49]. However, 
changing from infliximab to adalimumab in a patient with 
sufficiently controlled CD might lead to worse outcomes 
[50]. For infliximab, the SONIC study was able to show 
that the efficacy can be increased by a combination with 
azathioprine [33]. However, the potential risks could also 
increase during combination therapy [51].
Available data for infliximab suggest that the thera-
peutic effects of infliximab biosimilars are equivalent to 
the infliximab originator [8]. The development of bio-
similars will make this substance class economically more 
attractive [52]. Biosimilars for adalimumab are expected 
in the last quarter of 2018.
Vedolizumab
Vedolizumab is an antibody, which inhibits the homing 
of T cells to the gut by interaction with α4β7-integrins [53]. 
This mechanism is more specific than that of natalizumab, 
which inhibits α4-integrin and is able to cause progressive 
multifocal leukoencephalopathy in patients with CD [54]. 
In some countries (e.g., USA), natalizumab is approved for 
therapy-refractory CD. The GEMINI-2 study was able to 
demonstrate the superiority of vedolizumab to induce and 
maintain remission compared to placebo in CD over 2 years 
of observation [55]. Recently, the positive clinical effect was 
also observed in a meta-analysis. A disadvantage is the pro-
nounced latency of therapeutic effect (6–12 weeks) in CD, 
which makes vedolizumab less attractive for induction of 
remission. Patients with a failed anti-TNFα therapy showed 
less response to vedolizumab than anti-TNFα naïve pa-
tients and it took even more time until clinical remission 
was superior to the placebo group [56]. A typical side effect 
of vedolizumab is nasopharyngitis; however, in general, this 
substance seems to be well tolerated [57]. This is probably a 
result from the mainly local mechanism of action (Fig. 2).
Ustekinumab
Ustekinumab is a monoclonal antibody, which inhibits 
the p40 subunit of interleukin-12 (IL-12) and IL-23. These 
cytokines mainly interact with type 1 T-helper cells (Th1) 
and Th17 cell subsets [58]. In the UNITI-1 and UNITI-2 
studies, clinical remission and a clinical response induced 
by Ustekinumab was observed in active CD. Moreover, lev-
els of CRP and calprotectin were reduced on administration 
of therapy. The IM-UNITI study was able to demonstrate 
the potential of Ustekinumab for maintenance of remission 
over 44 weeks [59]. In the UNITI trials and in patients with 
psoriasis, no relevant major side effects were observed so 
far. However, potential adverse effects by immunosuppres-
sion cannot be excluded at that point.
New Substances in the Pipeline – Reason to Hope
CD is heterogenous and only a part of the patients will 
respond to approved substances. Moreover, a remarkable 
number of patients show secondary non-response after a 
variable duration of time. These limitations substantiate 
the strong need for new potent and well-tolerated drugs.
Mongersen is an antisense nucleotide, which binds the 
mRNA of SMAD7 (Mothers against decapentaplegic ho-
molog 7; https://www.genenames.org/cgi-bin/gene_sym-
bol_report?hgnc_id=HGNC:6773) [60]. This in turn 
strengthens the TGFβ signaling pathway, which exerts pre-
dominantly anti-inflammatory effects [61]. After very 
promising results were achieved in a phase II study, [62] 
the currently performed phase III was not able to detect 
a b
Fig. 2. Endoscopic response to  vedolizumab 
in a patient with Crohn’s disease. Patient 
data: female, 33 years old. a Without ve-
dolizumab and (b) after 6 months vedoli-
zumab.
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any advantage in an interim analysis in comparison to pla-
cebo [63]. Therefore, this study was interrupted and we 
have to wait for subgroup analyses.
The orally delivered substance filgotinib is an inhibitor 
of Janus-kinase 1 (JAK1) [64]. In a randomized, double-
blinded phase II trial, filgotinib was effective in the induc-
tion of clinical remission, but it failed to reach an endo-
scopic improvement (n = 174). Filgotinib seems to increase 
the risk of infections [65]. Two phase III studies are cur-
rently recruiting patients for further investigation of thera-
peutic and potential side effects (NCT02914600, 
NCT02914561). Upadacitinib (ABT-494) is another oral 
JAK1 inhibitor. A randomized, double-blind study was 
able to demonstrate the potential of Upadacitinib to induce 
clinical and endoscopical response in patients with mod-
erate-to-severe CD (n = 220). The side effects were similar 
to other JAK inhibitors. Phase III trials have been started 
(NCT03345836, NCT03345849, NCT03345823) [66].
Unlike ustekinumab, risankizumab inhibits the p19 
subunit of IL-23, and thus the cytokine IL-12 is not af-
fected. In a randomized, double-blinded phase II trial, ri-
sankizumab was able to induce clinical remission in pa-
tients with moderate-to-severe CD. There were no rele-
vant differences concerning adverse effects between the 
placebo and the treatment group [67]. Currently, phase 
III trials with risankizumab in CD are recruiting 
(NCT03105128, NCT03104413, NCT03105102).
The manipulation of the intestinal microbiome in CD 
represents another interesting therapeutic approach. 
While substantial data for probiotics or fecal microbiome 
transfer in CD is still missing, [68] the application of ri-
faximin could have positive effects [69]. Rifaximin has 
limited effects on the intestinal microbiome but could 
also induce effects on epithelial cells, for example, by an-
tagonizing the TNFα-receptor [69]. In a randomized, 
double-blind phase II trial with 402 patients, the admin-
istration of 1,600 mg Rifaximin per day induced clinical 
remission in patients with moderately active CD [70]. 
Only a few patients withdrew therapy due to side effects, 
and there were no significant differences concerning ad-
verse effects between placebo and treatment groups. The 
effect of rifaximin is further investigated in phase III stud-
ies (NCT02240108, NCT02240121, NCT03185611).
Individualized Therapy – The Agony of Choice
To make a decision for or against an immunosuppres-
sive therapy after the first flare in CD is not simple for 
each patient. Not only therapeutic side effects and the po-
tential therapeutic benefit must be considered but also 
risk factors for the individual disease course. According 
to different studies, young age at diagnosis, demand for 
steroids during the first flare and the presence of an ileo-
colonic or perianal disease are risk factors for a severe or 
complicated disease course [8, 71, 72]. Moreover, the fail-
ure of reaching mucosal healing is also a negative predic-
tor [8, 73]. To decide if the individual patient could prof-
it from a more aggressive “top-down” strategy, these risk 
factors have to be taken into account [74].
Due to the development of new substances in the recent 
past, we are now in the pleasant situation to offer several 
potent substances to our patients for maintenance of remis-
sion. Indeed, it is difficult to decide which of these drugs is 
optimal for the individual patient. Some meta-analyses 
compared the therapeutic efficacy and observed a potential 
superiority of the anti-TNFα antibodies adalimumab and 
infliximab [44, 45]. However, due to differences in the pa-
tient populations and lack of head-to-head studies, no gen-
eral recommendation for one substance against others is 
justified. Instead, the disease history and risk factors, as well 
as the patient’s preferences and local costs must be consid-
ered for an optimized individual therapy management.
The mentioned general orientation points are helpful 
but not sufficient in the clinical routine for the specific 
patient. It would be interesting to know the response of 
the patient before starting therapy. This knowledge would 
spare a lot of time, especially when drugs with a pro-
nounced latency of therapeutic effect, such as vedolizum-
ab, are applied. Moreover, side effects by individual inef-
fective substances could be avoided.
Atreya et al. [76] were able to test a priori the response 
to anti-TNFα antibodies and vedolizumab. Here, patients 
underwent a fluorescence endomicroscopy during colo-
noscopy with the staining of membrane-bound TNFα or 
α4β7-integrin. In patients with a high density of these re-
ceptors on the epithelium, the probability of a clinical re-
sponse was significantly higher [76]. Greater studies will 
have to confirm these results, yet we are convinced that 
this is a promising approach.
Fistulae – Prominence of Medical Therapy
Approximately half of the patients with CD are affect-
ed by one or more fistulas. These are mainly localized at 
the perianal region but can also occur at other sites (e.g., 
entercutaneous, enteroenteric) [77].
Concerning perianal fistulae, a simple form is differ-
entiated from complex perianal fistulae. For sufficient as-
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sessment of the fistulae and optimal therapy, a pelvis MRI 
scan is recommended. In the case of a symptomatic sim-
ple perianal fistula, a combination of an antibiotic thera-
py (ciprofloxacin and/or metronidazole) and Seton place-
ment is the standard therapy. Some meta-analyses were 
able to demonstrate a positive effect of these antibiotic 
therapies; however, this impact endures only for a limited 
period of time [77, 78].
In patients with simple perianal fistulas and therapy 
failure or in patients with complex perianal fistulae, the 
addition of infliximab or adalimumab and more exten-
sive surgical methods are recommended [77, 79]. For 
infliximab, a randomized placebo controlled study 
showed a significant improvement concerning the 
 complete closure of fistulae after 54 weeks (36 vs. 19%) 
[80]. The addition of ciprofloxacin to adalimumab led 
to a higher fistula closure rate than adalimumab alone 
[81].
However, still a remarkable proportion of fistulae can-
not be treated sufficiently. Therefore, new avenues have 
been explored in the therapy of fistulae. One promising 
approach is the local application of mesenchymal stem 
cells (MSC). Due to their low immunogenic potential, 
which is partly ascribed to the weak presentation of anti-
gens by their major histocompatibility complex (MHC-I) 
and no expression of MHC-II, allogenic transplantations 
without human leukocyte antigen matching are also pos-
sible [82]. In a randomized, double-blind, placebo-con-
trolled study, the local application of MSC led to a signifi-
cant higher amount of combined (clinical plus radiologi-
cal) remission than saline solution, which was used as 
placebo (50 vs. 34%; n = 212). Here, the number of all 
adverse events was similar in both study groups, whereas 
the treatment-related adverse events were higher after ap-
plication of placebo than MSC (29 vs. 17%). The main ad-
verse local effects were anal abscess and proctalgia [83]. A 
recent meta-analysis, where most of the patients derived 
from the study above, showed that the therapeutic success 
is greater in new fistulas than in chronic fistulas, and the 
usage of adipose-derived MSC seems to be superior to 
those derived from the bone marrow [84]. In summary, 
the local application of MSC seems to be an attractive ther-
apy of fistulae; however, further work has to address the 
standardization of these cells [85], and potential risks like 
carcinogenesis cannot be excluded at this point of time 
[82].
Conclusion
In the years gone by, several new targeted substances 
have enriched the therapeutic options in CD. Due to 
some drugs with promising results in phase II trials (fil-
gotinib, rifaximin, risankizumab, upadacitinib) we are 
looking into the future with cautious optimism. As a re-
sult of the growing number of therapeutic agents, an in-
dividualized therapy will become more and more impor-
tant. The local application of MSC might improve fistula 
healing. We believe that the optimization of drug formu-
lations, nutrition and the specific manipulation of the in-
testinal microbiome represent further important research 
topics in the upcoming years.
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